IQVIA Holdings Inc. $IQV Stock Holdings Lessened by Running Oak Capital LLC

Running Oak Capital LLC trimmed its position in IQVIA Holdings Inc. (NYSE:IQV) by 16.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 76,219 shares of the medical research company’s stock after selling 14,527 shares during the quarter. IQVIA makes up approximately 2.2% of Running Oak Capital LLC’s portfolio, making the stock its 6th biggest holding. Running Oak Capital LLC’s holdings in IQVIA were worth $17,181,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Alliancebernstein L.P. lifted its holdings in shares of IQVIA by 1.2% in the third quarter. Alliancebernstein L.P. now owns 3,597,572 shares of the medical research company’s stock worth $683,323,000 after buying an additional 41,643 shares in the last quarter. Boston Partners purchased a new stake in IQVIA in the third quarter valued at approximately $676,698,000. Artisan Partners Limited Partnership raised its stake in IQVIA by 4.9% in the third quarter. Artisan Partners Limited Partnership now owns 3,433,957 shares of the medical research company’s stock valued at $652,246,000 after purchasing an additional 161,085 shares in the last quarter. Invesco Ltd. raised its stake in IQVIA by 15.3% in the third quarter. Invesco Ltd. now owns 2,773,984 shares of the medical research company’s stock valued at $526,891,000 after purchasing an additional 367,204 shares in the last quarter. Finally, Nordea Investment Management AB raised its stake in IQVIA by 12.3% in the third quarter. Nordea Investment Management AB now owns 2,314,219 shares of the medical research company’s stock valued at $421,257,000 after purchasing an additional 253,759 shares in the last quarter. 89.62% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on the stock. Royal Bank Of Canada assumed coverage on shares of IQVIA in a research note on Tuesday, March 3rd. They issued an “outperform” rating and a $221.00 target price on the stock. Citigroup lowered their target price on shares of IQVIA from $230.00 to $200.00 and set a “neutral” rating on the stock in a research note on Friday, February 6th. Wall Street Zen downgraded shares of IQVIA from a “buy” rating to a “hold” rating in a research note on Saturday. JPMorgan Chase & Co. lowered their target price on shares of IQVIA from $255.00 to $225.00 and set an “overweight” rating on the stock in a research note on Friday, February 6th. Finally, Morgan Stanley set a $240.00 target price on shares of IQVIA in a research note on Wednesday, February 11th. Two analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $226.63.

IQVIA Trading Up 0.1%

IQV stock opened at $167.49 on Monday. The company has a market capitalization of $28.42 billion, a PE ratio of 21.31, a price-to-earnings-growth ratio of 1.62 and a beta of 1.39. IQVIA Holdings Inc. has a one year low of $134.65 and a one year high of $247.04. The company’s 50 day moving average price is $173.38 and its two-hundred day moving average price is $204.31. The company has a debt-to-equity ratio of 2.09, a quick ratio of 0.75 and a current ratio of 0.75.

IQVIA (NYSE:IQV) last posted its quarterly earnings results on Thursday, February 5th. The medical research company reported $3.42 EPS for the quarter, topping the consensus estimate of $3.40 by $0.02. The firm had revenue of $4.36 billion for the quarter, compared to the consensus estimate of $4.24 billion. IQVIA had a net margin of 8.34% and a return on equity of 30.50%. The business’s revenue was up 10.3% compared to the same quarter last year. During the same period last year, the firm posted $3.12 earnings per share. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. As a group, analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.